Featured Research

from universities, journals, and other organizations

Microneedle vaccine patch boosts flu protection through robust skin cell immune response

Date:
March 6, 2012
Source:
Emory University
Summary:
Recent research found that microneedle vaccine patches are more effective at delivering protection against influenza virus in mice than subcutaneous or intramuscular inoculation. A new, detailed analysis of the early immune responses helps explain why the skin is such fertile ground for vaccination with these tiny, virtually painless microneedles.

Microneedle patch.
Credit: Image courtesy of Emory University

Recent research found that microneedle vaccine patches are more effective at delivering protection against influenza virus in mice than subcutaneous or intramuscular inoculation. A new, detailed analysis of the early immune responses by the Emory and Georgia Tech research team helps explain why the skin is such fertile ground for vaccination with these tiny, virtually painless microneedles.

The research was published was recently published in the online journal MBio.

The skin, in contrast to the muscles, contains a rich network of antigen-presenting cells, which are immune signaling cells that are essential to initiating an immune response. The researchers found that microneedle skin immunization with inactivated influenza virus resulted in a local increase of cytokines important for recruitment of neutrophils, monocytes and dendritic cells at the site of immunization. All these cells play a role in activating a strong innate immune response against the virus.

Microneedle vaccination also may lead to prolonged depositing of antigen -- the viral molecules that are the targets of antibody responses. Such a prolonged antigen release could allow more efficient uptake by antigen-presenting cells. In addition, activated and matured dendritic cells carrying influenza antigen were found to migrate from the skin- an important feature of activating the adaptive immune response.

The research was led by first author Maria del Pilar Martin, PhD and Richard W. Compans, PhD, Emory professor of microbiology and immunology. Other authors included William C. Weldon, Dimitrios G. Koutsonanos, Hamed Akbari, Ioanna Skountzou, and Joshy Jacob from Emory University and Vladimir G. Zarnitsyn and Mark R. Prausnitz from Georgia Tech.

"Our research reveals new details of the complex but efficient immune response to influenza virus provided by microneedle skin patches," says Compans. "Despite the success of vaccination against influenza, the virus has many subtypes, mutates rapidly and continues to elude complete and long-term protection, and therefore requires annual vaccination with an updated vaccine each year.

"New vaccine formulations and delivery methods such as vaccine-coated microneedle patches could provide an improved protective response, which would be of particular benefit to those at high risk of related complications.

Vaccine delivery to the skin by microneedles is painless, and offers other advantages such as eliminating potential risks due to use of hypodermic needles."

The studies were supported by grants from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Biomedical Imaging and Bioengineering, which are part of the National Institutes of Health. Dr. Martin was supported by a fellowship from the Emory/UGA Influenza Pathogenesis and Immunology Research Center, a NIAID Center of Excellence for Influenza Research and Surveillance.


Story Source:

The above story is based on materials provided by Emory University. Note: Materials may be edited for content and length.


Journal Reference:

  1. Maria del Pilar Martin, William C. Weldon, Vladimir G. Zarnitsyn, Dimitrios G. Koutsonanos, Hamed Akbari, Ioanna Skountzou, Joshy Jacob, Mark R. Prausnitz, and Richard W. Compans. Local Response to Microneedle-Based Influenza Immunization in the Skin. mBio, March/April 2012 DOI: 10.1128/mBio.00012-12

Cite This Page:

Emory University. "Microneedle vaccine patch boosts flu protection through robust skin cell immune response." ScienceDaily. ScienceDaily, 6 March 2012. <www.sciencedaily.com/releases/2012/03/120306073011.htm>.
Emory University. (2012, March 6). Microneedle vaccine patch boosts flu protection through robust skin cell immune response. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/03/120306073011.htm
Emory University. "Microneedle vaccine patch boosts flu protection through robust skin cell immune response." ScienceDaily. www.sciencedaily.com/releases/2012/03/120306073011.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins